•   George Lundberg, MD

    This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.


  •   George Lundberg, MD

    Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

    Go to full article published by Targeted Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.